

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Psychiatry*

**Manuscript NO:** 88822

**Title:** Tanshinone IIA improves Alzheimer's disease via RNA nuclear-enriched abundant transcript 1/microRNA-291a-3p/member RAS oncogene family Rab22a axis

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03478911

**Position:** Associate Editor

**Academic degree:** PhD

**Professional title:** Chief Technician, Founder and CEO, Research Assistant Professor

**Reviewer's Country/Territory:** South Korea

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-10-11

**Reviewer chosen by:** Yu-Lu Chen

**Reviewer accepted review:** 2023-12-22 22:36

**Reviewer performed review:** 2023-12-24 03:11

**Review time:** 1 Day and 4 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Novelty of this manuscript	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Good <input type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No novelty
Creativity or innovation of this manuscript	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No creativity or innovation

<b>Scientific significance of the conclusion in this manuscript</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Good <input checked="" type="checkbox"/> Grade C: Fair <input type="checkbox"/> Grade D: No scientific significance
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous
	Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The authors attempted to study the related mechanisms of Tanshinone IIA (Tan-IIA) by applying its neuroprotective effect to Alzheimer's disease. The study is interesting, but there are some issues to revise. 1. A Methodology should describe how the AD mouse model was established. 2. Scale bars are missing in Figure 1b. 3. Figure 2 is difficult to read due to poor readability. 4. A description of the theoretical background for A $\beta$ 1-42 is missing. 5. In Figure 2, although the increase in SOD by 5 $\mu$ M of Tan-IIA is not clear, the amount of ROS is relatively well reduced as compared with a low dose of Tan-IIA or A $\beta$ 1-42 treated group. This is illogical. 6. According to Figure 3, the expression of NEAT1 is associated with increased ROS, and AD is associated with decreased mir-291a-3p. However, it is wondering why NEAT1 shows a tendency to increase with the expression of mir-291a-3p in Figure 3q and r. This comment also applies to the results in Figure 4e. Does this indicate that expression is suppressed by mir-291a-3p binding of the relevant factors? If so, this phenomenon should already be spontaneously presented in NCS under the AD condition. 7. In Figure 5, changes in factors resulting from the introduction of mir-291a-3p in diseased condition cells should have been



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [office@baishideng.com](mailto:office@baishideng.com)  
**<https://www.wjgnet.com>**

investigated.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** *World Journal of Psychiatry*

**Manuscript NO:** 88822

**Title:** Tanshinone IIA improves Alzheimer's disease via RNA nuclear-enriched abundant transcript 1/microRNA-291a-3p/member RAS oncogene family Rab22a axis

**Provenance and peer review:** Unsolicited manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03478911

**Position:** Associate Editor

**Academic degree:** PhD

**Professional title:** Chief Technician, Founder and CEO, Research Assistant Professor

**Reviewer's Country/Territory:** South Korea

**Author's Country/Territory:** China

**Manuscript submission date:** 2023-10-11

**Reviewer chosen by:** Jing-Jie Wang

**Reviewer accepted review:** 2024-01-24 05:18

**Reviewer performed review:** 2024-01-24 05:27

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** office@baishideng.com  
<https://www.wjgnet.com>

statements

Conflicts-of-Interest: [ ] Yes [Y] No

#### **SPECIFIC COMMENTS TO AUTHORS**

There was a need for additional experiments, but it was understood that they did not have the funds and time. Except that, all concerns have been well addressed. There is no additional issue to raise.